SIGA Reports Financial Results for Three and Six Months Ended June 30, 2026

* $37 Million of TPOXX Sales Generated in the Second Quarter * Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and six months ended June 30, 2026.

“In the second quarter, we delivered approximately $37 million of TPOXX to three customers: $24 million of IV TPOXX to the U.S. strategic national stockpile and $13 million of oral TPOXX to two international customers,” stated Diem Nguyen, Chief Executive Officer. “With product deliveries across the U.S., Europe, and the Asia- Pacific region, spanning multiple formulations, SIGA continues to execute its long-term plan of selling TPOXX across a diverse range of regions and customers.”